Potential Role of microRNA 410 and BIRC7 Pathways in Recurrent Spontaneous Miscarriage
Launched by NESMA GAMAL · Dec 12, 2022
Trial Information
Current as of January 22, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the potential role of certain biological pathways, specifically microRNA 410 and BIRC7, in understanding recurrent spontaneous miscarriages. Recurrent spontaneous miscarriage (RSA) is defined as having two or three miscarriages in a row or not too far apart, and it affects about 1% to 5% of women of childbearing age. The exact causes of these miscarriages can be complex and vary from person to person, and for many women, the reasons remain unexplained.
To participate in this trial, women aged 20 to 30 who have experienced two or three consecutive or closely timed miscarriages with the same partner may be eligible. The study aims to gather more information about these miscarriages to help improve outcomes for future pregnancies. If you join the trial, you can expect to undergo some tests and assessments to better understand your situation. It's important to know that women with only one miscarriage, known causes for their miscarriages, cancer, chronic illnesses, or those over 30 will not be eligible to participate.
Gender
FEMALE
Eligibility criteria
- • Inclusion Criteria: maternal age is between 20 to 30 years and Gestational age before abortion less than 24 weeks.
- • Female with unexplained two or three consecutive or discontinuous miscarriages with the same sexual partner
- Exclusion Criteria:
- • 1. Female with one miscarriage
- • 2. Female with explained causes of miscarriage
- • 3. Female with cancer
- • 4. Female with chronic illness.
- • 5. Pregnant women above 30
About Nesma Gamal
Nesma Gamal is a dedicated clinical trial sponsor committed to advancing medical research through innovative and ethical study designs. With a focus on improving patient outcomes, Nesma Gamal collaborates with healthcare professionals and research institutions to facilitate the development of novel therapies across various therapeutic areas. Leveraging a robust network of resources and expertise, the organization prioritizes patient safety and regulatory compliance while striving to deliver meaningful results that contribute to the medical community and enhance quality of care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Assiut, Assuit, Egypt
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Similar Trials